An assessment of the onset and duration of action of olopatadine nasal spray.
OBJECTIVE
Seasonal allergic rhinitis (SAR) is a highly prevalent disease. This study was conducted to evaluate the onset and duration of action of three concentrations of olopatadine nasal spray.


METHODS
This was a randomized, double-blind, single-dose, placebo-controlled study, conducted in an environmental exposure chamber in patients with SAR. A total of 320 patients were exposed to ragweed allergen in the chamber and randomized to olopatadine nasal spray 0.2%, 0.4%, 0.6%, or placebo nasal spray. Symptoms (sneezing, runny, itchy, and stuffy nose) were self-assessed during a 12-hour study period.


RESULTS
All concentrations of olopatadine nasal spray provided clinically meaningful reductions in total nasal symptom scores at 30 minutes compared to the placebo. Olopatadine nasal spray 0.6% was significantly more effective (P < 0.05) than placebo nasal spray at all time-points starting at 90 minutes post-dose and continuing over 12 hours.


CONCLUSIONS
Olopatadine nasal spray 0.6% demonstrated a fast onset of action and maintained an effect for at least 12 hours after dosing.
Allied Research International, Mississauga, ON, Canada. ppatel@allied-research.com
Piyush
P
Patel
Peter S
PS
Roland
Bradley F
BF
Marple
Paul J
PJ
Benninger
Harriet
H
Margalias
Michael
M
Brubaker
Sally F
SF
Beezley
Susan F
SF
Beezley
Margaret
M
Drake
Susan L
SL
Potts
G Michael
GM
Wall
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D000336:Aerosols; D000368:Aged; D000485:Allergens / Q000009:adverse effects; D031164:Ambrosia / Q000009:adverse effects; D018926:Anti-Allergic Agents / Q000008:administration & dosage*; D003990:Dibenzoxepins / Q000008:administration & dosage*; D004311:Double-Blind Method; D004780:Environment, Controlled; D004781:Environmental Exposure; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000069605:Olopatadine Hydrochloride; D017060:Patient Satisfaction; D010919:Placebos; D011058:Pollen / Q000009:adverse effects; D006255:Rhinitis, Allergic, Seasonal / Q000145:classification / Q000517:prevention & control*; D012449:Safety; D013997:Time Factors; D016896:Treatment Outcome
D000336:Aerosols; D000485:Allergens; D018926:Anti-Allergic Agents; D003990:Dibenzoxepins; D010919:Placebos; D000069605:Olopatadine Hydrochloride